Proven Industry Leadership

Jamie Platt_BW_edited.jpg

Jamie Platt PhD, MB (ASCP)

CEO & Founder

Jamie Platt has more than 15 Years of Leadership in Next Generation Sequencing and Clinical Diagnostics. She has propelled and directed a global $4.7B Fortune 500 diagnostics provider into the emerging genomics market through adoption of NGS technology; Spearheaded the development & validation of the first NGS-based HIV test for a large commercial reference lab (secured NYS approval) and increased revenue by $1M within 6 months of launch. Jamie has a strong track record of building NGS-based Genomics programs with FDA-aligned, design control development QMS and ISO 15189 readiness for growth from clinical into Pharma services markets.

  • Assay Development and Validation

  • Commercialization

  • High-Complexity Molecular Testing

  • Emerging Technology Market Assessment

  • Implementation of New Technologies in Clinical Diagnostics

  • Clinical Trials for Pharma and Device Manufacturers

  • Genomics program development and pipeline strategies

  • Strategic development and M & A’s

Selected Peer Reviewed Publications

  1. CLSI.Nucleic Acid Sequencing Methods in Diagnostic Laboratory Medicine; Approved Guideline – Second Edition.CLSI document MM09-A2. Wayne, PA. Clinical and Laboratory Standards Institute; 2014.

  2. Development and Validation of a Next-Generation Sequencing Assay for  and   Variants for the Clinical Laboratory. 2015. PLoS ONE 10(8): e0136419. doi:10.1371/journal.pone.0136419

  3. Comparison of Genotypic and Phenotypic HIV Type 1 Tropism Assay:  Results from the Screening Samples of Cenicriviron Study 202, a Randomized Phase II Trial in Treatment-Naïve Subjects.  AIDS Research and Human Retroviruses. February 2014, 30(2): 151-159. doi:10.1089/aid.2013.0123.

  4. A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment-Experienced Patients.  2012. PLoS ONE 7(9): e46334. doi:10.1371/journal.pone.0046334

Network of Industry Professionals

Bridgenomics has access to over 2,500+ professional network of KOLs, leaders, development scientists, end users, and investors. Including:

  • High-complexity CLIA Lab Directors (ABMGG, HCLD(ABB), ABMM, ABMLI)

  • Medical Directors with NGS experience

  • Quality Specialists and Regulatory Experts (ASQ CQPA and others)

  • Licensed, NGS-experienced Medical Technologists, including California (CGMBS)

  • Field Application Specialists and Molecular Assay Development Scientists (including PhDs)

  • Experienced Bioinformaticians, Linux gurus, and IT Security Experts

  • Six Sigma Black Belts and Lean for Six Sigma and Design for Six Sigma experts

  • Medical writers and marketing experts